ArticleVirology journal2025
Genetic characteristics of human bocavirus in children with acute respiratory tract infections during 2023 in Beijing, China.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Human bocavirus (HBoV) is an emerging pathogen associated with pediatric respiratory and gastrointestinal infections, yet its genetic diversity remains understudied. The aberrant global resurgence of other respiratory viruses after the COVID-19 pandemic has raised concerns regarding significant evolutionary shifts in viral genetic profiles. Accordingly, this study characterized HBoV isolates that circulated in Beijing during 2023 by analyzing 1,442 pediatric respiratory samples associated with acute respiratory tract infections. Among 43 HBoV-positive cases with a 2.98% detection rate, 11 complete genomes were sequenced and classified as HBoV1 through phylogenetic analysis. Amino acid substitutions in VP1, including the prevalent N474S mutation (95.3% frequency in GenBank), were predicted via structural modeling to alter hydrogen-bonding networks, potentially enhancing viral stability. Entropy analysis confirmed the high variability of VP1, whereas selective pressure analysis revealed conserved sites under purifying selection in the NP1 and VP1 proteins. Notably, the S79N substitution in NP1 introduced a putatively N-glycosylation site while a putatively O-glycosylation site was lost in four isolates, may suggesting functional implications. No recombination events were detected. These findings provide critical insights into the molecular evolution of HBoV1 and inform future research on antiviral strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.